According to the eye of the sky information shows that there are these three companies involved in the company's participation in the company's participation in the Beijing San Li Heze Biotechnology Co. 2021 to carry out "non-ST-segment elevation acute coronary artery syndrome (NSTE-ACS)" patients of the I clinical trial, has been completed All subjects have been enrolled in the trial, and data analysis and summarization of the clinical trial is underway.
CGCC Cellular Genetic Engineering Co., Ltd. is a life science and technology innovative enterprise with the core vision of developing "precision medicine".